Castle Biosciences (NASDAQ:CSTL) Stock Price Target Raised at KeyCorp

Key Points

• KeyCorp raised its price target on Castle Biosciences to $40 from $35 and reiterated an “overweight” rating, implying about 17% upside from the prior close.
• Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $44.88, though ratings range from sell to strong buy.
• Castle reported third-quarter revenue above expectations and a narrower-than-forecast loss, and raised its 2026 revenue guidance to $385 million–$395 million.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) had its price objective raised by KeyCorp from $35.00 to $40.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. KeyCorp's price target suggests a potential upside of 16.96% from the company's previous close.

Several other equities research analysts have also recently weighed in on CSTL. Robert W. Baird set a $36.00 price target on shares of Castle Biosciences in a research report on Friday, July 31st. Weiss Ratings restated a "sell (d-)" rating on shares of Castle Biosciences in a research report on Thursday, October 29th. Wall Street Zen raised shares of Castle Biosciences from a "hold" rating to a "buy" rating in a research note on Sunday, November 1st. BTIG Research upped their price objective on shares of Castle Biosciences from $40.00 to $44.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Finally, Mizuho assumed coverage on shares of Castle Biosciences in a report on Thursday, October 29th. They set an "outperform" rating and a $60.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Castle Biosciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $44.88.

Castle Biosciences Stock Performance

Castle Biosciences stock opened at $34.20 on Friday. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $1.04 billion, a PE ratio of -51.82 and a beta of 1.00. The firm has a fifty day simple moving average of $34.28 and a two-hundred day simple moving average of $28.57. Castle Biosciences has a twelve month low of $17.72 and a twelve month high of $44.28.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.22. The firm had revenue of $101.95 million for the quarter, compared to analysts' expectations of $92.77 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. Research analysts expect that Castle Biosciences will post -1.29 EPS for the current year.

Insider Activity

In related news, COO Kristen Oelschlager sold 4,153 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $35.95, for a total value of $149,300.35. Following the completion of the transaction, the chief operating officer directly owned 13,356 shares of the company's stock, valued at $480,148.20. This represents a 23.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek J. Maetzold sold 8,580 shares of the stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $31.91, for a total transaction of $273,787.80. Following the completion of the transaction, the insider directly owned 12,484 shares of the company's stock, valued at approximately $398,364.44. The trade was a 40.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 126,184 shares of company stock valued at $4,324,506. Corporate insiders own 6.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CSTL. Global Retirement Partners LLC purchased a new position in shares of Castle Biosciences during the second quarter valued at approximately $26,000. NFSG Corp bought a new stake in shares of Castle Biosciences in the 3rd quarter worth approximately $36,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Castle Biosciences in the 3rd quarter worth approximately $55,000. Quantbot Technologies LP purchased a new stake in shares of Castle Biosciences in the 2nd quarter worth approximately $62,000. Finally, State of Wyoming purchased a new stake in shares of Castle Biosciences in the 2nd quarter worth approximately $117,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

Trending Headlines about Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: Q3 2026 revenue rose 24% year over year to $102.9 million, above analysts’ expectations. The company’s loss of $0.13 per share was also narrower than consensus estimates of roughly $0.35–$0.38 per share. Castle Biosciences Reports Third Quarter 2026 Results
• Positive Sentiment: Castle raised its 2026 revenue guidance to $385 million–$395 million, up from $365 million–$375 million. TissueCypher test report volume grew 47% year over year in Q3, and the company cited a target of 50%–52% volume growth, supporting the improved outlook. Castle Biosciences signals 2026 revenue outlook
• Negative Sentiment: The company still posted a quarterly loss, and its loss per share widened from $0.02 in the year-ago quarter to $0.13. Persistent unprofitability may temper the positive impact of revenue growth and improved guidance. Castle Biosciences reports Q3 loss, beats revenue estimates

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.